Novo Medi Sciences Launches Nexipox Plus Varicella Vaccine with Enhanced Stability Technology for Indian Market
核心洞察
Novo Medi Sciences (搜索) has launched Nexipox Plus (搜索), a next-generation varicella vaccine featuring a 2X trehalose-based stabilizer system that replaces conventional gelatin and mannitol formulations.
Clinical trials demonstrated impressive efficacy with 98% seroconversion rates and a 35.4-fold geometric mean rise in antibody titers following a two-dose schedule.
The vaccine addresses unique Indian healthcare challenges through enhanced thermal stability and reduced allergic reaction risk, with DCGI approval for use from 12 months of age.
Novo Medi Sciences (搜索) Pvt. Ltd., a pharmaceutical company with 80 years of expertise in biological products, has announced the launch of Nexipox Plus (搜索), representing what the company calls "the most recent innovation in Varicella vaccine since decades." The vaccine has been specifically developed to address the clinical, environmental, and operational needs of Indian patients and healthcare settings.
Advanced Stabilization Technology
The key innovation in Nexipox Plus (搜索) lies in its 2X trehalose-based stabilizer system, which replaces conventional stabilizers such as gelatin and mannitol. This formulation advancement addresses the inherent thermolability of live attenuated varicella (搜索) vaccines, a critical challenge in maintaining vaccine potency and stability.
According to the company, this stabilizer system enhances viral stability, preserves potency, and significantly reduces the risk of allergic reactions and antigen crystallization-related issues. The formulation is designed to support more reliable vaccine performance across storage, handling, and administration phases.
Clinical Performance Data
Clinical trials conducted on Indian patients have demonstrated strong immunogenic performance. Forum Bhagat, managing director of Novo Medi Sciences (搜索), reported that "the results of the clinical trial on Indian Patients has shown high seroconversion rates of 98% following a two-dose schedule, supported by a 35.4-fold geometric mean rise in antibody titres, indicating a robust immune response and effective protection against varicella virus."
The vaccine has also demonstrated a favorable safety profile in clinical studies, with no serious adverse events causally linked to the vaccine in comparative clinical trials. The removal of gelatin from the formulation further supports improved tolerability.
Clinical Significance and Expert Perspective
Dr. Nitin K. Shah, consultant pediatrician and pediatric hemato-oncologist in Mumbai, emphasized the clinical advancement represented by Nexipox Plus (搜索). "While stability and safety are already well established in varicella (搜索) vaccination, the real clinical advancement with Nexipox Plus lies in its enhanced immunogenicity," Dr. Shah stated. "By building on a stable and reliable formulation, the use of 2× trehalose alongside advances in formulation and manufacturing has translated into stronger and more consistent immune responses, offering tangible benefits in routine immunisation and reinforcing clinician confidence."
Regulatory Approval and Market Impact
Nexipox Plus (搜索) has received approval from the Drugs Controller General of India (DCGI) for use from 12 months of age. The vaccine launch aligns with broader public health goals of reducing disease burden and improving vaccination compliance, particularly given the high prevalence of chickenpox (搜索) in India.
The product is designed with affordability, scalability, and operational reliability in mind, supporting adoption in private practice and strengthening the overall immunization ecosystem. The company notes that the vaccine supports adoption in private practice settings while contributing to the broader immunization infrastructure.
Global Expansion Plans
The vaccine is backed by patented technology across 156 countries, reflecting strong global regulatory readiness. Novo Medi Sciences (搜索) is evaluating international expansion strategies based on public health needs and sustainable supply considerations.
With this launch, Novo Medi Sciences (搜索) reinforces its focus on formulation-led vaccine innovation, positioning itself as the only company to proactively upgrade varicella vaccine specifically for Indian conditions. The company describes this as delivering advancements that enhance stability, safety, and clinical confidence in modern immunization practices.